HEALTHQUARTZ
Ipsen is acquiring a Swiss biotech for up to $800 million to treat kidney transplant infections
Ipsen, a French drugmaker, is acquiring Swiss biotech Memo for up to $800 million. The upfront payment is 200 million euros, targeting a kidney transplant infection with no approved treatments.
Mentioned
Related Signal
Adjacent reporting
- Ipsen is buying U.S. blood cancer startup Kartos for up to $1.75 billion
- GSK in talks to buy cancer biotech Nuvalent for more than $9bn
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
- Incyte strikes up to $2bn deal for blood disorder biotech